How does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?

Front Neurol · 2013 · PMC3640198 · PMID 23641231

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Effect on MRI measures Fingolimod therapy demonstrated a highly significant reduction in inflammatory disease activity (T1 Gd-enhancement, new, or enlarging T2-lesions), burden of disease (volume of T2/PD hyperintensive lesions), and tissue loss and destruction [volume of T1 hypointense lesions (black holes)].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.